Branded Legacy, Inc. Expands into Biotech and Medical Devices with Acquisition of Bio Legacy Evaluative Group
Branded Legacy, Inc. (OTC: BLEG) has acquired Bio Legacy Evaluative Group, marking its entry into the biotech and medical devices sector with a focus on addressing global health challenges.
Branded Legacy, Inc. (OTC: BLEG), a diversified holdings company known for its focus on the health and wellness sector, has officially completed its acquisition of Bio Legacy Evaluative Group. This strategic move, finalized on July 31, 2025, was executed through an all-stock deal valued at $1.5 million in Preferred D shares. The acquisition signifies Branded Legacy's ambitious expansion into the biotech and medical devices industry, aiming to tackle pressing global health issues such as the addiction epidemic and inefficiencies in vaccine distribution.
Under the leadership of CEO Amin Janmohamed, Bio Legacy Evaluative Group brings to the table a patented all-in-one intranasal naloxone device. This innovation is set to tap into a rapidly growing market, projected to expand from $371 million in 2022 to over $1.16 billion by 2032. Additionally, Bio Legacy's technology for the nasal delivery of vaccines and cold-chain therapies presents a promising avenue for addressing some of the most critical challenges in healthcare today.
The terms of the acquisition include performance-based conversion milestones, a two-year lock-up period, and a commitment of $1 million towards research and development following the company's uplisting to OTCQB. This underscores Branded Legacy's dedication to innovation and its strategic approach to growth within the biotech sector.
For further details on this acquisition, interested parties can view the full press release here. More information about Branded Legacy Inc. and its initiatives can be found on the company's official website here.